СИСТЕМНАЯ СКЛЕРОДЕРМИЯ -МУЛЬТИДИСЦИПЛИНАРНАЯ ПРОБЛЕМА

1. <div><p>Гусева Н.Г. Системная склеродермия. М.: Медицина, 1975;269 с.</p><p>Rodnan G.P. Progressive systemic sclerosis (Scleroderma). In: Immunological diseases, 3rd ed. Boston, 1978;66:1109-41.</p><p>Гусева Н.Г. Системная склеродермия. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008;447-66.</p><p>Varga J., Abraham В. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.</p><p>Tindall A., Matucci-Cerenic M., Muller-Lander U. Future targets in the managements of systemic sclerosis. Rhеumatology 2009;48:49-53.</p><p>Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rhеum Dis Clin North Am 2008;34:57-71.</p><p>Тrojаnоwska М. Сellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 2010 (on-line).</p><p>Cutolo M., Matucci-Cerenic M. Naifold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheum 2007;25(5):663-5.</p><p>Matucci-Cerenic M., Allanore Y., Czirjak L. et al. The challenge of early systemic sclerosis for the ЕULAR Scleroderma Trial and research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009;68(9):1377-80.</p><p>Haohulla E., Coghlan J.G. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis 2004;63:1009-14.</p><p>Korn J., Mayes M., Matucci-Cerenic M. et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, on oral endothelin receptor antagonist. Arthr Rheum 2004;50:3985-93.</p><p>Алекперов Р.Т., Корзенева Е.Г., Александрова Е.Н. и др. Плейотропные эффекты статинов при системной склеродермии. Тер арх 2011 (в печати).</p><p>Nevskaya T., Ananieva L., Bykovskaya S. et al. Autologous progenitor cell implantation as novel therapeutic intervention for ischaemic digits in systemic sclerosis. Rhеumatology 2009;48(1):61-4.</p><p>Denton Ch. Assesing long-term outcomes in PAH-SSс. In: Evolving treatment stratigies for PAH-SSc optimising management of an aggressive disease. Ist Systemic Sclerosis World Congress, 2010, Italy.</p><p>Sü tö G., Czirjak L. Oesophageal involvement in scleroderma. Clin Exp Rheum 2009;27(3, Suppl. 54):2-4.</p><p>Venables P. Overlap syndromes. In: Rhеumatology. Еds М. Hochberg, A. Silman et al. NY: Mosby, 2003;II;1573-80.</p><p>Старовойтова М.Н., Десинова О.В., Гусева Н.Г. Перекрестные формы системной склеродермии. Науч-практич ревматол 2007;1:52-8.</p><p>Десинова О.В. Перекрестная форма системной склеродермии: Автореф. дис. … канд. мед. наук. М., 2008.</p><p>Guseva I., Desinova O., Starovoytova M. et al. HLA-DRB1 polymorfism in systemic sclerosis overlap-syndromes in russian population. Ann Rheum Dis 2005;64(Suppl. 3):113.</p><p>Гусева Н.Г. Смешанное заболевание соединительной ткани и перекрестные формы системных заболеваний соединительной ткани. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа 2008;517-27.</p><p>Nelson J., Furst D., Maloney S. et al. Microchimerism and HLA compatible relationships of pregnancy in scleroderma. Lancet 1998;351:559-62.</p><p>Mosca M., Curcio M., Lapi S. et al. Correlations of Y-chromosome microchimerism with disease activity in patients with SLE: analysis of preliminary data. Ann Rheum Dis 2003;62(10):651-4.</p><p>Rak J., Pagni P., Tiev T. et al. Male microchimerism and HLA-compatibility in French women with scleroderma: a difficult profile in limited and diffuse subset. Rhеumatology 2009;48(4):363-6.</p><p>Гусева Н.Г. Системная склеродермия и псевдосклеродермические синдромы. М.: Медицина, 1993;268 с.</p><p>Hausten U., Anderegg U. Silica-induced scleroderma: clinical and experimental aspects. J Rhеumatol 1998;25:1917-26.</p><p>Steen V.D. Occupational scleroderma. Curr Opin Rheum 1999;11:490-4.</p><p>Black C.M., Pereira S., McWhiter A. et al. Genetic susceptibility to scleroderma-like syndrome in symptomatic and asymptomatic workers exposed to vinyl chloride. J Rhеumatol 1986;13:1059-62.</p><p>Невская Т.А. Клинико-морфологические и иммунологические аспекты ранней системной склеродермии: Автореф. дис. … канд. мед. наук. М., 2004.</p><p>Steen V.D., Medser T.A. Long-term outcomes of scleroderma renal crisis. Ann Int Med 2000;133(8):600-3.</p><p>Launay D., Sitbon O., Le Paves J. еt al. Long-term outcomes of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rhеumatology 2010;49(3):490-500.</p><p>Distler J., Distler O. Imatinib as a novel therapeutic approach for fibrotic disorders. Rhеumatology 2009;48(1):2-4.</p></div><br />